Back to search

Article

SARS-COV-2 nasopharyngeal viral load change in a multicenter randomized clinical trial comparing early therapies for COVID-19 in non-hospitalized adults with high risk of severe COVID-19 (the MONET TRIAL)

2025-01-17

Abstract excerpt

<title>Abstract</title> <p>Although <italic>in vitro</italic> studies suggest that neutralization by monoclonal antibodies (mAbs) against SARS CoV2 Omicron sub lineages is reduced, <italic>in vivo</italic>virological response data are lacking. MONET (EudraCT: 2021-004188-28) was multi-centric phase 4 open-label parallel randomized clinical trial, conducted in Italy over 2022-2023, to assess the efficacy of sotrov...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c284385f-27c8-594e-beea-a05ce4b2ae5f
DOI
10.21203/rs.3.rs-5715907/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
SARS-COV-2 nasopharyngeal viral load change in a multicenter randomized clinical trial comparing early therapies for COVID-19 in non-hospitalized adults with high risk of severe COVID-19 (the MONET TRIAL)DOI 10.21203/rs.3.rs-5715907/v1
SARS-COV-2 nasopharyngeal viral load change in a multicenter randomized clinical trial comparing early therapies for COVID-19 in non-hospitalized adults with high risk of severe COVID-19 (the MONET TRIAL)Semantic proximity
<i>In vivo</i> virological efficacy of monoclonal antibodies and direct antiviral agents against the SARS-CoV-2 BA.1 and BA.2 Omicron sublineagesSemantic proximity
Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 and BA.5 subvariant predominance: a systematic literature reviewSemantic proximity
Therapeutic Combinations in Mild or Moderate COVID-19 to Reduce Nasopharyngeal Carriage of SARS-CoV-2 and Prevent Severe COVID-19 in Côte D’Ivoire: A Pragmatic Phase IIb Randomized Controlled Clinical Trial. The ANRS COV01 INTENSE-COV TrialSemantic proximity
REGEN-COV Antibody Combination in Outpatients With COVID-19 – Phase 1/2 ResultsSemantic proximity
Characteristics and outcomes of patients with COVID-19 at high-risk of disease progression receiving sotrovimab, oral antivirals or no treatment in EnglandSemantic proximity
Real-world Use of Nirmatrelvir-Ritonavir in COVID-19 Outpatients During the Emergence of Omicron Variants BA.2/BA2.12.1Semantic proximity
Emulation of a target trial from observational data to compare effectiveness of Casirivimab/Imdevimab and Bamlanivimab/Etesevimab for early treatment of non-hospitalized patients with COVID-19Semantic proximity
Real-Life Comparison of Mortality in Non-Hospitalised Patients with SARS-CoV-2 Infection at Risk for Clinical Progression Treated with Molnupiravir or Nirmatrevir Plus Ritonavir During the Omicron Era in Italy: A Nationwide, Observational StudySemantic proximity
Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19Semantic proximity
Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trialSemantic proximity
Systematic review and patient-level meta-analysis of SARS-CoV-2 viral dynamics to model response to antiviral therapiesSemantic proximity
Select a neighboring publication to make it the new centre.